When Pirfenidone, a TGFβ antagonist and antifibrotic agent, was administered in conjunction with doxorubicin, a standard of care chemotherapeutic, there was a statistically significant decrease in tumor growth and lung metastasis [88]. This evidence concerns the gene TGFB1 and neoplasm.